# Phase III Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Symptomatic Knee Osteoarthritis

> **NCT04333160** · PHASE3 · COMPLETED · sponsor: **Bone Therapeutics S.A** · enrollment: 746 (actual)

## Conditions studied

- Symptomatic Osteoarthritis of the Knee

## Interventions

- **DRUG:** JTA-004
- **DEVICE:** Hylan G-F 20
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT04333160
- **Lead sponsor:** Bone Therapeutics S.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-10
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-12-09
- **Target enrollment:** 746 (ACTUAL)
- **Last updated:** 2022-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04333160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04333160, "Phase III Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Symptomatic Knee Osteoarthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04333160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*